VOOPOO
4.7.2022 09:17:05 CEST | Business Wire | Press release
VOOPOO’s 2022 "More Than Infinity " virtual product launch was held on June 29, 2022, where VOOPOO took 30 minutes to review its brand story during the past 8 years since its founding, expounding the connection between the “infinity symbol” and the brand spirit and demonstrating its commitment to creating infinite new possibilities using technology in 3 chapters. Meanwhile, the event was highlighted by 3 POD products featuring VOOPOO’s most cutting-edge technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005586/en/
A very important theme at the virtual event was telling the growth story of VOOPOO since its founding 8 years ago. Evolving from an atomization chip solution provider to today’s industry leader of open electronic atomization, VOOPOO has driven the positive development of the industry through a series of disruptive innovations while undergoing its own brand metamorphosis. In addition, since VOOPOO started the globalization strategy last year, it has opened branches in the United States, the United Kingdom, Indonesia, Germany, France, Canada, and Malaysia, and will open more in the future to strengthen localized operation in the local market. VOOPOO has also insisted on strengthening its global influence in the global electronic atomization field by setting up brand flagship stores and launching APPs in more regions.
As another essential part of the event, VOOPOO released the three latest Pod products, of which two V-series products, namely VMATE E and VMATE Infinity Edition, were unveiled for the first time. Both products are equipped with the newly upgraded cartomizer, using the 5A freshness seal technology to lock the fresh taste and aroma of the e-liquid, while the Fresnel lens texture design can effectively reduce the e-liquid’s exposure to light, preserving the fresh taste for users. The material of the cartridge is specially added with silver ions with 99%+ effective antibacterial performance.
The third product Drag Q which was previously released came back with a new CMF Infinity Edition. As a POD product, Drag Q has subverted the industry's understanding of POD products with its expert-level performance in intelligent pressure control and taste restoration. At the virtual launch, the VOOPOO global brand ambassador also explained in detail the core drive of VOOPOO’s leapfrog development, i.e., the investment in “user-centered” R&D. So far, VOOPOO has launched three pioneering atomization platforms catering to different users -- PNP, TPP, ITO , and has developed two GENE chips for different product functions -- GENE AI and GENE TT . It is with the continuous optimization and innovation in atomization technology that VOOPOO wins trust and support of consumers.
Infinite connections: join hands with 100,000+ customers and 50,000,000+ fans to build an electronic atomization culture
The last chapter was dedicated to the customers and millions of fans who marched forward hand in hand with VOOPOO. In the past 8 years, VOOPOO has cooperated closely with more than 100,000 offline outlets, and has won more and more consumers with high-quality products and continuous market investment. Its market achievements are the evidence of mutual benefit and win-win cooperation with partners. On a global scale, more than 50 million users have become loyal fans of VOOPOO. They not only spur VOOPOO to continue to create products that are ahead of the times but also become part of the electronic atomization culture in the VOOPOO ecosystem. VOOPOO announced that the first flagship stores, being part of the VOOPOO ecosystem, will open in the UK and Indonesia for close interaction with VOOPOO fans.
VOOPOO took 30 minutes to demonstrate the connection between VOOPOO’s development strategy, innovative spirit, brand culture and the infinity symbol, while the 3 newly launched products will be worthy of the expectations of the market and the industry.
About VOOPOO
VOOPOO is a leading brand of open pod system and has rapidly risen through DRAG products, which have been widely acclaimed globally in a short period of time. VOOPOO focuses on building two core technology platforms of [Chip] and [Atomization]. VOOPOO has creatively developed GENE.AI, GENE.TT and other chips. In addition, VOOPOO independently developed three Atomization Platforms, which are TPP,PNP,ITO, aiming at differentiated users. VOOPOO has four major product series - ARGUS, DRAG, VINCI, and V-series(Doric). VOOPOO will continue to develop more national markets in the future, aiming to build one of the most influential global brands.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005586/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release
Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP
Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release
Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp
KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release
Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen
Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release
Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR
Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
